Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield NE Lab Prior Auth Policy | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - NebraskaPolicy M.89

    MA General Approach to Laboratory Testing (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.89 alerts

    Get alerted when Policy M.89 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines general coverage criteria and preauthorization expectations for genetic/molecular and other laboratory tests not addressed elsewhere, including carrier, familial variant, single-gene/multigene panels, prenatal diagnosis, and other laboratory tests; applies to Blue Cross Blue Shield - Nebraska members and ordering providers subject to payer rules.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA General Approach to Laboratory Testing (Preauthorization Required)
    Policy CodePolicy M.89
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewOct 17, 2024
    Next Review DateJan 1, 202743d
    Key ActionObtain prior authorization and submit the exact test code and supporting clinical documentation before ordering listed genetic or laboratory tests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8distinct criteria sections
    CLIALaboratory certification required
    18+adult-onset age threshold
    VUS excludedVUS policy
    >=80listed test codes (approx.)

    Coverage Criteria and Policy Scope

    Known Familial Variant Analysis

    Targeted mutation analysis for a known familial variant for a genetic condition may be considered reasonable and necessary when ALL of the following are met:

    Known familial variant criteria: A. The member is 18 years or older (if the condition is adult-onset); B. The member has a close relative with a known pathogenic or likely pathogenic variant causing the condition; C. An association between the gene and disease has been established.
    Not reasonable: Targeted mutation analysis for a known familial variant of uncertain significance is considered not reasonable and necessary.
    Other indications: Targeted mutation analysis for a known familial variant for a genetic condition is considered not reasonable and necessary for all other indications.

    Targeted Carrier Screening

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA General Approach to Laboratory Testing (Preauthorization Required)
    Policy CodePolicy M.89
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewOct 17, 2024
    Next Review DateJan 1, 202743d
    Key ActionObtain prior authorization and submit the exact test code and supporting clinical documentation before ordering listed genetic or laboratory tests.
    SourceLink
    On This Page
    Coverage Criteria and Policy ScopeCovered Indications and Clinical ContextsProcedure and Test CodesProvider Responsibilities, Prior Authorization, and DocumentationOrdering, Counseling, and Submission RequirementsNot Covered / ExclusionsFrequency and Re-testing GuidanceDefinitions and Technical TermsBackground and RationalePolicy Dates and Revision History

    Carrier screening via full gene sequencing or targeted mutation analysis may be considered reasonable and necessary when ALL of the following are met:

    Carrier screening primary criteria: A. The member is considering pregnancy or is currently pregnant; B. The genetic disorder is a recessive condition with childhood onset; C. One of the following: 1) The member has a close relative with a known pathogenic or likely pathogenic variant associated with the disorder; OR 2) The member’s reproductive partner is a carrier for the genetic disorder; OR 3) The member or reproductive partner are members of a population with carrier rate ≥ 1% for the condition; OR 4) The member or reproductive partner has a first- or second-degree relative affected with the genetic disorder.
    Not reasonable: Carrier screening for a genetic disorder is considered not reasonable and necessary for all other indications.

    Single-gene or Multigene Panel Analysis

    Single-gene or multigene panel testing may be considered reasonable and necessary when ALL of the following are met:

    Panel testing criteria: A. The member displays clinical features of the suspected genetic condition; B. Diagnosis remains uncertain after appropriate clinical evaluation and other standard laboratory tests/imaging have been performed; C. The test has clinical validity; D. The test has clinical utility as demonstrated by at least one of the following: 1) determines if a therapeutic intervention is effective or harmful; OR 2) directly impacts clinical management; OR 3) determines prognosis; OR 4) provides or refines estimates of natural history/recurrence risk; E. There is no known familial pathogenic or likely pathogenic variant for which targeted testing would be more appropriate; F. Non-genetic causes for the clinical features have been ruled out; G. An association between the gene or panel and the disease has been established.
    Not reasonable: Genetic testing via single-gene or multigene panel analysis is considered not reasonable and necessary for all other indications.

    Prenatal Diagnosis for Single-Gene Disorders

    Prenatal diagnostic testing (amniocentesis, CVS, PUBS) for single-gene disorders may be considered reasonable and necessary when ALL of the following are met:

    Prenatal diagnostic criteria: A. Member meets at least one: 1) at least one biological parent has a known pathogenic variant for an autosomal dominant condition; OR 2) both biological parents are known carriers of an autosomal recessive condition; OR 3) one biological parent is suspected or known carrier of an X-linked condition; OR 4) member has history of a previous child with a genetic condition and is suspected to have germline mosaicism; AND B. The natural history of the disease is well-understood with high likelihood of high morbidity; AND C. The genetic test has adequate sensitivity and specificity to guide clinical decision-making and residual risk is understood.
    Exclusions: Prenatal diagnosis for adult-onset single-gene disorders (e.g., BRCA1/2) is not reasonable and necessary; Prenatal diagnosis for variants of unknown significance (VUS) is not reasonable and necessary; Prenatal diagnosis is not reasonable and necessary for all other indications.

    Other Laboratory Tests

    Other laboratory tests may be considered reasonable and necessary when ALL of the following are met:

    Other lab test criteria: A. The member displays relevant clinical features consistent with the intended use of the test; B. The test has clinical validity; C. The test has clinical utility as demonstrated by at least one of: 1) determines if a therapeutic intervention is effective or harmful; OR 2) directly impacts clinical management; OR 3) determines prognosis; OR 4) provides or refines estimates of natural history/recurrence risk; AND D. Testing is performed in a CLIA-approved laboratory.
    Not reasonable: Other laboratory tests are considered not reasonable and necessary for all other indications.

    Single-gene or multigene panel coverage criteria

    Covered when testing meets general clinical utility and diagnostic criteria

    Primary clinical indications: Situations where a definitive diagnosis informs causality, prognosis, and treatment; newborn screening per the Secretary’s Discretionary Advisory Committee recommendations; discovery of medically actionable secondary findings with available treatments; patients with complex disorders (e.g., autism, intellectual disability); patients with rare disorders or those diagnosed by chromosome analysis or microarray; and genetic conditions where testing may inform management despite limited guidance.

    From policy section 'General Criteria for Single Gene or Multigene Panel Analysis'

    Clinical utility considerations

    Additional utility considerations that support coverage decisions

    Family and societal clinical utility: Enables at-risk family member testing and informed reproductive decision-making; resolves diagnostic odyssey; provides access to support groups; and supports research and long-term population health benefits.

    Policy lists these as clinical utility considerations

    Tests listed (informational for authorization process)

    Listed tests requiring preauthorization (descriptive entries only)

    Listed tests: Each code and full description entry in this section identifies laboratory tests under Policy M.89 that are subject to the preauthorization requirement; no additional clinical criteria are provided in these chunks.

    See individual code descriptions for intended clinical context (e.g., oncology, transplant, neurology).

    Listed tests requiring policy consideration

    Code list for tests subject to the policy

    Listed tests: Specific CPT codes enumerated in this section are subject to the policy's preauthorization and coverage evaluation.

    No detailed 'when covered' criteria in these chunks; refer to other policy sections.

    General preauthorization coverage condition

    Covered when preauthorization is obtained for listed procedures

    Preauthorization requirement: Authorization must be requested for the specific CPT/PLA code(s) listed in this section prior to service.

    This excerpt lists codes/examples by test type and molecular pathology level; medical necessity criteria are elsewhere in the full policy.

    General prior authorization requirement

    Coverage is predicated on prior authorization for the listed molecular and multianalyte tests and panels.

    Listed tests require preauthorization: Prior authorization is required for the molecular pathology and genomic/multianalyte assay CPT codes enumerated in this section.

    Specific clinical criteria and medical necessity logic are not present in this excerpt; refer to other parts of the policy for condition-specific criteria.

    Prenatal diagnostic testing (amniocentesis, CVS, PUBS) for single-gene disorders is permitted only when the policy’s specific clinical criteria are met. Required conditions include parental carrier or known pathogenic variant status (autosomal dominant parent affected, both parents carriers for an autosomal recessive disorder, or suspected/known carrier for an X‑linked condition), or a history suggesting germline mosaicism; the disease’s natural history must be well understood with high morbidity, and the test must have adequate sensitivity and specificity to guide decision making. Importantly, prenatal diagnosis for adult-onset single-gene disorders (e.g., BRCA1/2) is considered not reasonable and necessary and is excluded under this policy.

    The policy aligns with professional guidance that predictive or prenatal testing for adult-onset conditions should generally be deferred when results will not affect pregnancy or childhood medical management. The National Society of Genetic Counselors and AAP/ACMG emphasize deferring such testing for minors or prenatal contexts that do not change clinical care, and recommend pre-test genetic counseling to discuss implications, limitations, and ethical concerns before ordering testing for adult-onset conditions.

    Where specific coverage criteria are not met, multiple sections state testing is not reasonable and necessary. Examples include targeted familial variant analysis when the familial change is a variant of uncertain significance (VUS), carrier screening performed outside the stated reproductive indications, single-gene or multigene panel testing that does not satisfy the policy’s clinical-feature, diagnostic‑uncertainty, clinical‑validity, and clinical‑utility requirements, prenatal testing for VUS or for adult‑onset disorders, and other laboratory tests performed outside CLIA‑approved laboratories.

    Covered Indications and Clinical Contexts

    Familial variant testing, targeted carrier screening, single-gene/multigene panels, prenatal diagnostic testing, and other laboratory tests where listed clinical criteria are met

    Familial variant testing, targeted carrier screening, single-gene/multigene panels, prenatal diagnostic testing, and other laboratory tests where listed clinical criteria (clinical features, clinical validity, clinical utility, and laboratory certification) are met.

    Covered indications summary: Pre-test and post-test genetic counseling is strongly advised; targeted testing is preferred when a known pathogenic familial variant exists; testing must meet the condition-specific clinical criteria described in this policy.

    Diagnostic evaluation when test result will inform causality, prognosis, treatment, newborn screening per advisory committee, or when testing can reveal actionable secondary findings

    Diagnostic evaluation when test result will inform causality, prognosis, treatment, newborn screening per advisory committee, or when testing can reveal actionable secondary findings.

    Diagnostic utility criteria: Testing is clinically appropriate when results will inform causality, prognosis, or treatment decisions; when newborn screening recommendations apply; when medically actionable secondary findings may be discovered and acted upon; or when testing addresses complex or rare disorders where results will alter management or recurrence risk counseling.

    Rare constitutional/heritable disorders — structural variant identification by optical genome mapping

    Rare constitutional or heritable disorders where structural variant identification is required.

    Optical genome mapping indications: Optical genome mapping (and related whole-genome analyses) may be considered when identification of large structural variants (copy number variations, inversions, insertions, translocations) is clinically indicated for rare constitutional or heritable disorders.

    Oncology MRD and tumor-specific ctDNA/cfDNA analyses — examples and codes enumerated

    Oncology minimal residual disease and tumor-specific ctDNA/cfDNA analyses — examples and codes enumerated.

    Oncology MRD/ctDNA indications: Personalized or panel-based plasma ctDNA/cfDNA assays and methylation-based cfDNA assays may be considered when used for minimal residual disease detection, surveillance, or disease-burden assessment in oncology, using tests and codes listed in this policy.

    Various specialty indications as listed per test

    Various specialty indications as listed per test.

    Specialty-linked tests: Tests listed include clinical contexts across oncology, neurology, transplant medicine, nephrology, hepatology, cardiology, infectious disease, autoimmune, psychiatry, pulmonary, and gastroenterology; refer to individual code descriptions for the intended specialty use.

    Examples of clinical contexts linked to tests

    Examples of clinical contexts linked to tests — representative indications included in code descriptions.

    Example clinical contexts: Many code descriptions include indications such as myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia, solid tumors, hereditary cancer syndromes (e.g., Lynch, BRCA-related), cystic fibrosis, pharmacogenomics, and neurologic disorders (e.g., Huntington, Friedreich ataxia).

    Genetic diagnosis, pharmacogenetic testing, oncologic mutation analysis, HLA typing, and cytogenomic evaluations

    Genetic diagnosis, pharmacogenetic testing, oncologic mutation analysis, HLA typing, and cytogenomic evaluations as exemplified by listed genes and assays.

    Assay type examples: The policy enumerates gene-specific analyses, pharmacogenetic panels, HLA typing, methylation assays, cytogenomic microarray/optical mapping, and molecular pathology procedure levels; refer to code entries for details.

    Heritable, constitutional, and neoplastic disorders

    Heritable, constitutional, and neoplastic disorders — many gene examples are provided in code listings.

    Condition examples: Listed gene examples and panels represent conditions such as retinal disorders, hereditary breast/colon cancer syndromes, inherited cardiomyopathies, mitochondrial disorders, neuromuscular disorders, and various neoplasms.

    Procedure and Test Codes

    Listed PLA / Proprietary Laboratory Procedure Codesmixed
    0001URBC DNA HEA 35 AG 11 BLD GRP WHL BLD CMN ALLEL
    0009UONC BRST CA ERBB2 COPY NUMBER FISH AMP/NONAMP
    0010UNFCT DS STRN TYP WHL GENOME SEQUENCING PR ISOL
    0019UONC RNA WHL TRANSCIPTOME SEQ TISS PREDCT ALG
    0022UTRGT GEN SEQ ALYS NONSM LNG NEO DNA&RNA 23 GENES
    0023UONC AML DNA GNTYP INT TANDEM DUP DETCJ/NONDETCJ
    0035UNEURO CSF DETCJ PRION PRTN QUAKG CONF CONV QUAL
    0046UFLT3 GENE INT TANDEM DUPL VARIANTS QUANTITATIVE
    0055UCARD HRT TRNSPL 96 TARGET DNA SEQUENCES PLASMA
    0058UONC MERKEL CELL CARC DETCJ ANTB SERUM QUAN
    1–10 of 36
    1/4
    Covered/Listed Test CodesCPT | HCPCS | mixed
    0184UDO GNOTYP GENE ANALYSIS ART4 EXON 2
    0185UFUT1 GNOTYP GENE ANALYSIS FUT1 EXON 4
    0186UFUT2 GNOTYP GENE ANALYSIS FUT2 EXON 2
    0187UFY GNOTYP GENE ANALYSIS ACKR1 EXONS 1-2
    0188UGE GNOTYP GENE ANALYSIS GYPC EXONS 1-4
    0189UGYPA GNOTYP GENE ALYS GYPA INTRONS 1 5 EXON 2
    0190UGYPB GNOTYP ALYS GYPB INTRON 1 5 PSEUDOEXON 3
    0191UIN GNOTYP GENE ANALYSIS CD44 EXONS 2 3 6
    0192UJK GNOTYP GENE ANALYSIS SLC14A1 GEN PRMTR EXON 9
    0193UJR GNOTYP GENE ANALYSIS ABCG2 EXONS 2-26
    1–10 of 48
    1/5
    Other laboratory PLA/UC codes (sample)mixed
    0458UONC BREAST CA S100 A8&A9 ELISA TEAR FLUID ALG
    0465UONC UROTHELIAL CARC DNA QMSP 2 GENES ALG ALYS
    0466UCRD CAD DNA GWAS 564856 SNP TRGT VARIANT GNOTYP
    0467UONC BLDR DNA NGS 60 GEN&WHL GENOME ANEUP UR ALG
    0468UHEP NASH MIR-34A-5P A2M YKL40 HBA1C SRM&WHL BLD
    Other laboratory PLA/UC codes (sample continued)mixed
    0470UONC OROP DETCJ MRD NGS QUAN EVAL 8DNA CFHPV16&18
    0471UONC CLRCT CA QUAL RT-PCR 35 VRNT KRAS&NRAS GENES
    0479UTAU PHOSPHORYLATED PTAU217
    0493UTRNSPLJ MED QUANTIFICATION DDCFDNA NGS PLASMA
    0496UONC CLRCT CFDNA 8GENS MUT 7GENS MTHYLTN RT-PCR
    Additional PLA/UC codesmixed
    0500UAUTOINFLAM DS VEXAS SYND DNA UBA1 GENE MUT ALYS
    0503UNEURO ALZ DS BETA AMYL&TAU PRTN BLD LC-MS/MS ALG
    0506UGI BARRETTS ESOPHGL CELL DNA MTHYLTN ALYS NGS 89
    0508UTRNSPLJ MED QUAN DDCFDNA 40 SNPS PLASMA&URINE
    0511UONC SOL TUM CELL CUL 3D MICROENVIR 36+ RX PANEL
    Sample continuedmixed
    0535UPFAS LC-MS/MS PLASMA/SERUM QUANTITATIVE
    0536URBC AG FETAL RHD PCR ALYS EXON 4 RHD GENE&GAPDH
    0540UTRNSPLJ MEDICINE QUAN DD-CFDNA NGS ALYS PLASMA
    0541UCV DS HDL RCT CEC LC-MS/MS 5HDL-BD APO SERUM ALG
    0542UNEFRO RENAL TRNSPL URINE NMR 84 UR METABOLITES
    CMS/AMA CPT Category II/III and genomic codesmixed
    0003MLIVER DIS 10 ASSAYS SERUM ALGORITHM W/NASH
    0004MNUCLEOTIDE POLYMORPHISMS (SCOLIOSIS) 53 SNPS
    0006MONCOLOGY (HEPATIC) MRNA 161 GENES
    0011MONC PRST8 CA MRNA 12 GENES BLD PLSM & UR ALG
    81105HPA-1 GENOTYPING GENE ANALYSIS COMMON VARIANT
    Established molecular pathology CPT codesCPTCovered
    81161DMD DUPLICATION/DELETION ANALYSIS
    81162BRCA1&BRCA2 FULL SEQ ANALYS/FULL DUP/DEL ANALYS
    81163BRCA1 BRCA2 GENE ANALYSIS FULL SEQUENCE ANALYSIS
    81170ABL1 GENE ANALYSIS KINASE DOMAIN VARIANTS
    81171AFF2 GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    Listed gene analysis codes (sample fragment)CPT
    81177ATN1 GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81178ATXN1 GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81179ATXN2 GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81180ATXN3 GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81181ATXN7 GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81182ATXN8OS GENE ANALYSIS EVAL DETC ABNORMAL ALLELES
    Listed gene/molecular/microarray/methylation/translocation codesCPT
    81183ATXN10 GENE ANALYSIS EVAL DETC ABNORMAL ALLELES
    81184CACNA1A GENE ANALYSIS EVAL DETECT ABNOR ALLELES
    81185CACNA1A GENE ANALYSIS FULL GENE SEQUENCE
    81186CACNA1A GENE ANALYSIS KNOWN FAMILIAL VARIANT
    81187CNBP GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81188CSTB GENE ANALYSIS EVAL DETECT ABNORMAL ALLELES
    81189CSTB GENE ANALYSIS FULL GENE SEQUENCE
    81191NTRK1 TRANSLOCATION ANALYSIS
    81192NTRK2 TRANSLOCATION ANALYSIS
    81193NTRK3 TRANSLOCATION ANALYSIS
    1–10 of 121
    1/13
    Selected gene-specific CPT codes (partial list)CPT
    81317PMS2 GENE ANALYSIS FULL SEQUENCE
    81318PMS2 GENE ANALYSIS KNOWN FAMILIAL VARIANTS
    81319PMS2 GENE ANALYSIS DUPLICATION/DELETION VARIANTS
    81320PLCG2 GENE ANALYSIS COMMON VARIANTS
    81321PTEN GENE ANALYSIS FULL SEQUENCE ANALYSIS
    81322PTEN GENE ANALYSIS KNOWN FAMILIAL VARIANT
    Molecular pathology level CPT codesCPT
    81400MOLECULAR PATHOLOGY PROCEDURE LEVEL 1
    81401MOLECULAR PATHOLOGY PROCEDURE LEVEL 2
    81402MOLECULAR PATHOLOGY PROCEDURE LEVEL 3
    81403MOLECULAR PATHOLOGY PROCEDURE LEVEL 4
    81404MOLECULAR PATHOLOGY PROCEDURE LEVEL 5
    81405MOLECULAR PATHOLOGY PROCEDURE LEVEL 6
    81406MOLECULAR PATHOLOGY PROCEDURE LEVEL 7
    HLA typing codesCPT
    81370HLA CLASS I&II LOW HLA-A -B -C -DRB1/3/4/5&DQB
    81371HLA I&LI LOW RESOLUTION HLA-A -B&-DRB1
    81372HLA CLASS I TYPING LOW RESOLUTION COMPLETE
    81378HLA I&II HIGH RESOLUTION HLA-A -B -C AND -DRB1
    Covered CPT CodesCPT
    81406MOLECULAR PATHOLOGY PROCEDURE LEVEL 7 (listed under Level 6/7 context in this excerpt)
    81407MOLECULAR PATHOLOGY PROCEDURE LEVEL 8
    81408MOLECULAR PATHOLOGY PROCEDURE LEVEL 9
    81415EXOME SEQUENCE ANALYSIS
    81416EXOME SEQUENCE ANALYSIS EACH COMPARATOR EXOME
    81425GENOME SEQUENCE ANALYSIS
    81426GENOME SEQUENCE ANALYSIS EACH COMPARATOR GENOME
    81427GENOME RE-EVALUATION OF PREVIOUSLY OBTAINED GENOME SEQUENCE
    81432HEREDITARY BREAST CANCER-RELATED GENETIC SEQUENCE PANEL (>=14 genes)
    81434HEREDITARY RETINAL DISORDERS GEN SEQ ANALYSIS (>=15 genes)
    1–10 of 42
    1/5
    Clinical validity measures — sensitivity, specificity, PPV, NPV
    SensitivityProportion of people with the condition who have a positive test result
    SpecificityProportion of people without the condition who have a negative test result
    Positive predictive value (PPV)Among people with a positive test result, the proportion who have the condition
    Negative predictive value (NPV)Among people with a negative test result, the proportion who do not have the condition
    Panel gene counts or feature thresholds — exact values provided per code
    Blood-group/red-cell antigen panelsExamples specify gene/feature counts (e.g., 0246U: 16 blood groups predicting 51 RBC antigens; multiple PLA red cell genotyping entries list specific exons per antigen)
    Hematology and bleeding/platelet panelsNamed panels include explicit gene counts (eg, 0272U: 51 genes; 0274U: 43 genes; 0271U: 23 genes; 0276U: 23 genes)
    ctDNA/cfDNA oncology panelsSome assays list minimum gene/content counts (eg, 0428U: 56+ genes for targeted ctDNA) or panel-specific content descriptions
    Hereditary diagnostic panels (CPT examples)Policy lists minimum gene-count thresholds for named panels (eg, 81432 hereditary breast cancer >=14 genes; 81434 hereditary retinal disorders >=15 genes; 81435 hereditary colon cancer = 7 genes)
    DNA methylation site counts — site-count ranges for methylation assays
    >1000 sitesSome methylation assays report analysis of more than 1,000 sites (examples aggregated in policy)
    >5,000 sitesMultiple tests specify >5,000 sites (eg, 0620U hepatocellular carcinoma >5,000 sites; 0623U multiple sclerosis >5,000 sites)
    >10,000–20,000 sitesSeveral neuro/cardiac/psychiatric methylation assays specify >10,000 to >20,000 sites (eg, 0618U >10,000; 0617U >20,000; 0626U >20,000)
    >30,000 sitesAt least one dementia methylation assay specifies analysis of >30,000 sites (0616U)
    Variant sets — common variants vs full sequencing vs known familial vs duplication/deletion
    Common/targeted variant panelsTests limited to frequently observed pathogenic or clinically relevant variants are listed (eg, CPT entries for common variants like CYP2C9, G6PD)
    Full sequencing / comprehensive panelsFull gene or multi-gene sequence analysis entries are listed (eg, BRCA1/2 full sequence, G6PD full sequence, numerous multi-gene panels)
    Known familial variant vs VUSPolicy specifies targeted analysis for known familial pathogenic/likely pathogenic variants is appropriate; testing for familial variants of uncertain significance (VUS) is considered not reasonable and necessary
    Duplication/deletion analysesSeparate CPT descriptors identify duplication/deletion testing (eg, APC duplication/deletion, HBA1/HBA2 dup/del entries) as distinct variant sets
    Minimum genes per named panels — examples of gene-count thresholds
    Hereditary breast cancer panelsMust include sequencing of at least 14 genes (eg, ATM, BRCA1, BRCA2, PALB2, PTEN, TP53, etc.)
    Hereditary retinal disorders panelMust include sequencing of at least 15 genes (examples listed in policy)
    Hereditary colon cancer panelMust include analysis of at least 7 genes (eg, APC, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2)
    Inherited bone marrow failure syndromes (IBMFS)Sequence panel must include at least 30 genes (examples provided)

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Preauthorization required for unspecified laboratory/genetic testing

    Preauthorization is required for genetic and other laboratory tests not addressed elsewhere; requests must meet the policy’s clinical criteria for the test type (familial variant, carrier screening, single‑gene/multigene panels, prenatal diagnosis, or other laboratory tests).

    • Request prior authorization before performing tests covered by this policy.
    Prior Authorization

    Preauthorization required for listed PLA codes

    The listed proprietary PLA/unique laboratory procedure codes require prior authorization; providers must submit a procedure plus diagnosis code pair (use Quick Code Search to add code pairs) when requesting authorization.

    • Include both the procedure (PLA) code and the associated diagnosis code in the authorization request via Quick Code Search.
    Prior Authorization

    Preauthorization required for listed tests

    Preauthorization is required for the tests enumerated by code in the policy; providers must request prior authorization using the exact test code and descriptor shown in the code list when seeking coverage.

    • Order and submit the exact CPT/PLA code and test descriptor from the policy when requesting authorization.
    Prior Authorization

    Preauthorization required — listed laboratory tests governed by preauthorization

    The laboratory tests enumerated in this document are governed by the policy’s preauthorization process and require review prior to service; do not assume inclusion in the code list guarantees coverage without authorization.

    • Obtain preauthorization per Policy M.89 before performing listed laboratory tests.
    Prior Authorization

    Prior authorization required for listed molecular/genetic tests

    Prior authorization is required for the molecular and genetic CPT/HCPCS codes listed in the policy; providers must request authorization referencing the exact CPT or PLA code(s).

    • Reference the specific CPT/HCPCS code(s) (e.g., 81177–81182 and others listed) in prior authorization requests.
    Prior Authorization

    Preauthorization required for listed codes

    Preauthorization is required for the molecular pathology and genetic/cytogenomic procedure codes enumerated in this section; providers must request authorization referencing the exact CPT/PLA code(s) listed.

    • Submit the precise CPT/PLA code(s) from the policy when requesting prior authorization for molecular pathology procedures.
    Prior Authorization

    Prior authorization required — exome/genome and multianalyte assay codes

    Prior authorization is required for exome/genome sequence analysis and multianalyte assay codes (examples include exome/genome and multianalyte assay CPT codes listed); obtain authorization before testing.

    • Reference exome/genome and multianalyte CPT codes (e.g., 81415–81427, 815xx codes) in authorization requests.
    Note

    Preauthorization requirement — medical policies determine scientific validity and coverage

    BCBSN uses its medical policies to determine scientific validity and to administer plan benefits; certain laboratory tests require preauthorization per this policy and benefits are determined by the applicable contract terms.

    • Follow BCBSN preauthorization processes; the medical policy determines scientific validity but does not itself guarantee benefits.
    Step Therapy

    Prefer targeted familial variant testing when possible

    When a known pathogenic familial variant exists, ordering targeted familial variant analysis is preferred over broader single‑gene or multigene panel testing.

    • If a familial pathogenic/likely pathogenic variant is known, submit a request for targeted variant analysis rather than a broad panel.
    Documentation Required

    Required documentation to support medical necessity

    Document the member’s clinical features, prior evaluations (labs/imaging), familial variant status (if known), and evidence of the test’s clinical validity and utility to support medical necessity for authorization and claims.

    • Include relevant clinical signs/symptoms and prior diagnostic workup.
    • Indicate known familial variant status when applicable.
    • Provide rationale showing clinical validity/utility for the requested test.
    Documentation Required

    Pre-test counseling documentation

    Provide documentation of pre‑test genetic counseling (discussion of test performance, limitations, benefits, and alternatives) prior to ordering genetic tests, particularly for prenatal or predictive testing.

    • Document counseling content including benefits, limitations, sensitivity/specificity, and potential outcomes.
    • Recommend counseling by a genetic counselor or genetics‑expert clinician.
    Documentation Required

    Documentation to support preauthorization

    When requesting preauthorization, include the exact test code and the appropriate clinical documentation demonstrating how the request meets the policy’s clinical criteria.

    • Submit the precise CPT/PLA code and supporting clinical notes demonstrating medical necessity.
    • Use Quick Code Search to verify procedure+diagnosis code pairing for authorization.
    Billing Rule

    Required billing/test documentation

    Use the billing code and full test description listed in the policy for preauthorization and claims documentation; each listed test entry includes the billing code and description to be used.

    • Ensure claims and authorization requests use the exact code/description from the policy’s code list.
    Documentation Required

    Submission should cite listed test codes

    Submit preauthorization requests referencing the specific test code(s) listed in the policy (for example, gene analysis codes 81177, 81178, etc.) to obtain prior authorization.

    • Reference the exact CPT or PLA code(s) from the policy in the authorization submission.
    Documentation Required

    Use code-level descriptors for authorization

    When requesting authorization, reference the molecular pathology procedure level and code‑level descriptors (Levels 1–7 and examples) as shown in the policy to clarify analytic scope and match the requested service.

    • Include the molecular pathology procedure level (e.g., 81400–81406, or higher-level codes) and examples of gene/exon scope when applicable.
    Documentation Required

    Documentation and references

    Follow the policy references and disclaimers and provide any cited professional guideline support when submitting authorization requests; adhere to BCBSN preauthorization procedures.

    • Cite relevant professional guidance (NSGC, ACOG, AAP/ACMG) and include policy disclaimers as applicable in submissions.
    Note

    Provider responsibility and benefits determination

    Providers remain responsible for clinical decision‑making and patient care; benefits for a particular service are determined by the terms and conditions of the member’s benefit contract, not the policy alone.

    • Obtain benefit determination from the member’s contract even if the test meets policy criteria.
    Denial Risk

    Denial for VUS familial variant testing

    Targeted mutation analysis for a known familial variant of uncertain significance (VUS) is considered not reasonable and necessary and would be denied.

    • Do not request targeted familial testing for variants classified as VUS; such requests will be considered not reasonable and necessary.
    Denial Risk

    Denial for prenatal testing for adult-onset single-gene disorders

    Prenatal diagnostic testing for adult‑onset single‑gene disorders (e.g., BRCA1/2) is considered not reasonable and necessary and would be denied.

    • Do not submit prenatal diagnostic testing requests for known adult‑onset single‑gene disorders if pregnancy/childhood management will not be affected.
    Denial Risk

    Denial for non-CLIA laboratory testing

    Tests performed outside a CLIA‑approved laboratory are considered not reasonable and necessary and will be denied; ensure testing is performed in a CLIA‑approved laboratory.

    • Confirm the performing laboratory is CLIA‑approved before submitting authorization or claims.
    Billing Rule

    Code-pair entry requirement

    Use the Quick Code Search to submit both the procedure and diagnosis code pair; failure to enter the required procedure+diagnosis code pair or mismatched pairing may result in denial or hold for review.

    • Enter the procedure code first, then the diagnosis code, and click 'Add Code Pair' in Quick Code Search.
    • Ensure the diagnosis code aligns with the policy’s clinical criteria for the procedure.
    Denial Risk

    Preauthorization requirement (implied)

    Submitting requests without prior authorization for tests covered under the policy’s General Criteria for Other Laboratory Tests may trigger denial; obtain authorization before service.

    • Do not perform or bill for listed tests without first obtaining required prior authorization.
    Prior Authorization

    Preauthorization requirement — tests listed are subject to preauthorization per Policy M.89

    Tests listed in this document are subject to preauthorization per Policy M.89; lack of preauthorization may trigger denial under the policy.

    • Obtain prior authorization per Policy M.89 for listed tests to avoid denial.
    Prior Authorization

    Preauthorization required — document header indicates 'Preauthorization Required'

    The document header and policy text indicate 'Preauthorization Required' for laboratory testing under this policy; ordering providers must obtain authorization prior to service.

    • Ordering providers must request and receive preauthorization before performing tests covered by this policy.
    Prior Authorization

    Preauthorization requirement (general) — tests part of payer’s general preauthorization approach

    The tests enumerated throughout the policy are part of BCBSN’s general approach requiring preauthorization; failure to obtain authorization may result in denial or hold for review.

    • Verify authorization requirements for each listed CPT/PLA code prior to ordering.
    Prior Authorization

    Preauthorization required — molecular pathology and other listed laboratory tests

    Molecular pathology and other listed laboratory tests require prior authorization; ordering providers must obtain preauthorization and reference the listed CPT/PLA code when requesting authorization.

    • Include the exact code and test descriptor from the policy when submitting authorization requests for molecular pathology tests.
    Denial Risk

    Denial risk from lack of authorization

    Services may be denied if not authorized per the terms and conditions of the applicable benefit contract; the medical policy does not itself constitute authorization or guarantee coverage.

    • Obtain explicit authorization per member benefit contract; policies do not replace contractual benefit determinations.

    Ordering, Counseling, and Submission Requirements

    Note

    ORDERING REQUIREMENTS — genetic counseling involvement recommended; ordering guided by clinical evaluation and family history

    Ordering should be guided by clinical evaluation and family history; consider involving genetic counseling and ensure carrier screening is performed when appropriate (ideally preconception) with counseling documented.

    • Consider referral to a genetic counselor or genetics‑expert clinician for pre‑test counseling.
    • Document family history and clinical evaluation supporting the test request.
    Documentation Required

    Pre-test genetic counseling recommended

    Pre‑test genetic counseling by a genetic counselor or genetics‑expert clinician is recommended prior to prenatal or predictive testing; document counseling and informed consent discussions.

    • Document that the patient received pre‑test counseling including risks, benefits, limitations, and possible outcomes.
    • Recommend counseling especially for prenatal and predictive testing.
    Billing Rule

    Code-pair submission required for Quick Code Search/prior authorization

    Submission of both procedure and diagnosis code pairs is required for the Quick Code Search/prior authorization process; enter the procedure code then the diagnosis code to add the pair for review.

    • Use Quick Code Search: enter the procedure code, then the diagnosis code, and click 'Add Code Pair' to submit for review.
    Prior Authorization

    Ordering provider must request preauthorization and use the exact test code when ordering

    The ordering provider must request preauthorization and use the exact test code and descriptor from the policy when ordering to ensure the authorization matches the service.

    • Reference the exact CPT/PLA code and descriptor in the authorization request.
    Prior Authorization

    Preauthorization required for listed tests under Policy M.89 — ordering provider responsibilities implied

    Preauthorization is required for the tests listed under Policy M.89; ordering provider responsibilities are implied (obtain authorization, submit required documentation) though specific permitted ordering provider types are not detailed in the excerpt.

    • Ordering providers must obtain prior authorization and supply clinical documentation per the policy.
    Documentation Required

    Authorization requests should reference specific CPT code(s)

    Authorization requests should reference the specific CPT code(s) being ordered; the policy emphasizes citing the exact code(s) though ordering provider qualifications are not specified in the excerpt.

    • Include specific CPT code(s) (for example, 81177, 81178, 814xx codes) in authorization requests.
    Prior Authorization

    Preauthorization must be obtained — reference specific CPT/PLA code and descriptor

    Preauthorization must be obtained and the ordering provider should reference the specific CPT/PLA code and test descriptor when requesting authorization.

    • Ensure the authorization request cites the exact CPT/PLA code and the test descriptor from the policy’s code list.
    Prior Authorization

    Prior authorization required — ordering providers must obtain preauthorization

    Ordering providers must obtain prior authorization for listed tests; the excerpt indicates prior authorization is required though specific provider types allowed to order are not listed.

    • Obtain prior authorization before ordering listed molecular/genomic tests.

    Not Covered / Exclusions

    The policy identifies categories of testing that are not covered: testing of a familial or prenatal variant of uncertain significance (VUS) is considered not reasonable and necessary; prenatal diagnostic testing for adult-onset single-gene disorders (for example, hereditary cancer syndromes such as BRCA1/2) is excluded; and laboratory tests performed outside a CLIA‑approved laboratory are not covered. Providers should request preauthorization and supply documentation demonstrating the test meets the applicable clinical criteria and is performed in a CLIA‑approved laboratory.

    Prenatal genetic testing for known adult‑onset conditions and predictive genetic testing of minors for adult‑onset conditions are not recommended when the results will not affect pregnancy or childhood management. The policy references NSGC and AAP/ACMG guidance advising deferral of predictive testing of minors for adult‑onset disorders and recommending genetic counseling before considering prenatal testing for adult‑onset conditions.

    This excerpt primarily provides a code list of tests that are subject to the policy’s preauthorization process and does not explicitly mark the enumerated tests as not covered. Individual codes listed in this section are informational for authorization and must be evaluated against the policy’s clinical criteria during review.

    Within the portions of the document that list proprietary and algorithmic laboratory tests, there are no explicit per‑test exclusions stated in this excerpt. These entries function as identifiers for tests that require prior authorization; coverage determinations depend on whether the clinical criteria are met.

    The CPT code catalog fragment included here enumerates gene‑level analyses and molecular pathology entries but does not itself state explicit exclusions. These codes are subject to the policy’s preauthorization requirement and clinical review according to the general coverage criteria elsewhere in the policy.

    The sampled code catalog and descriptive entries in this excerpt do not list specific exclusions. They serve to identify tests that require review under Policy M.89; clinical justification and preauthorization are required to determine coverage on a case‑by‑case basis.

    This segment lists additional CPT entries and gene‑specific analyses but does not itself designate tests or indications as not covered. Coverage is determined by applying the policy’s clinical criteria and by obtaining required prior authorization for listed molecular pathology and genomic tests.

    Frequency and Re-testing Guidance

    Frequency limits — (placeholder)
    Frequency limitsNo explicit numeric frequency limits provided in the cited document chunks
    Practice implicationAuthorization decisions should rely on clinical criteria and test-specific indications rather than preset repeat intervals in these excerpts
    Exception guidanceWhen frequency rules are needed, refer to individual test entries or payer prior-authorization processes outside these chunks
    No frequency limits specified in these chunks
    Frequency limits statedNo frequency limits specified in the provided document chunks
    Implication for orderingPreauthorization and clinical criteria determine coverage rather than fixed per-test frequency rules in these excerpts
    Follow-upCheck payer-specific authorization portal or full policy text for any per-test frequency constraints not present here
    Chimerism analysis (81267, 81268) — post-transplant monitoring implied; no explicit frequency stated
    Chimerism CPT codes81267 (chimerism with comparison to baseline without cell selection); 81268 (with cell selection) are listed for post‑transplant monitoring contexts
    ContextCodes are included among molecular/genetic procedure listings; monitoring after transplant is implied by test descriptions
    Frequency guidanceNo explicit frequency or interval limitations are stated in the cited chunks — frequency not specified here
    Frequency limits — (no explicit data)
    Frequency limitsNo explicit frequency data available in the provided chunks
    ActionRely on clinical judgment and payer authorization rules for repeated testing requests
    NoteSpecific tests may have frequency guidance elsewhere in full policy or authorization system
    Exome/genome re-evaluation (81427) allowed when re-analysis of prior genome is performed (no specific frequency specified)
    Exome/genome re-evaluation (81427)Permitted when re-analysis of a previously obtained genome is performed (code 81427) — no specific repeat interval provided in these chunks
    Use caseMay be used when updated knowledge warrants re-evaluation of prior genome sequence data
    Authorization implicationPreauthorization required for exome/genome procedures listed; frequency or timing to be justified by clinical documentation

    Definitions and Technical Terms

    Adult-onset condition definition
    DefinitionAdult-onset condition: signs, symptoms, or manifestations typically begin after age 18 years
    RelevanceUsed to determine appropriateness of predictive or prenatal testing (testing for adult-onset conditions in minors generally deferred)
    Associated guidancePolicy references AAP/ACMG guidance on testing minors for adult-onset conditions
    Clinical validity definition
    DefinitionClinical validity: accuracy with which a test identifies a particular clinical condition
    ComponentsIncludes sensitivity, specificity, positive predictive value, and negative predictive value
    Role in coverageTest clinical validity is a required element for considering a test reasonable and necessary
    Clinical utility definition
    DefinitionClinical utility: the risks and benefits resulting from genetic test use; whether testing and subsequent interventions improve health outcomes
    ConsiderationsIncludes impact on therapeutic decisions, management, prognosis, recurrence risk, and potential harms of testing
    Evaluation frameworkClinical utility is assessed alongside analytic and clinical validity (eg, the ACCE model)
    Recessive condition definition
    DefinitionRecessive condition: disorder requiring pathogenic variants in both gene copies or hemizygous X-linked mutation in an individual with one X chromosome
    Implication for carrier screeningCarrier screening criteria reference recessive conditions with childhood onset as primary targets
    Family testingIdentification of carriers informs reproductive risk assessment
    Clinical validity / utility per cited literature
    Clinical validity / utility per literatureClinical validity assesses test accuracy (sensitivity, specificity, predictive values); clinical utility evaluates whether test results and interventions improve outcomes — frameworks cited include ACCE and NIH references
    SourcesCDC ACCE model and NIH/Hayes citations referenced in policy text
    ApplicationThese definitions underpin coverage determinations in the policy
    Optical genome mapping — definition and use for structural variant detection
    DefinitionOptical genome mapping: a method to identify large structural variants (copy number variations, inversions, insertions, translocations), used for rare constitutional/heritable disorders and oncology applications
    Example codes0260U, 0264U, 0267U, 0454U are listed for optical genome mapping or OGM-related structural analyses
    Clinical useApplied when genome-wide structural variant identification is required and may be combined with whole-genome sequencing
    cfDNA/ctDNA assays — definition and clinical uses
    DefinitioncfDNA/ctDNA assays: cell-free DNA or circulating tumor DNA analyses from plasma used for cancer detection, minimal residual disease (MRD) assessment, or methylation/panel-based testing
    ExamplesCodes such as 0340U (personalized MRD), 0428U (targeted ctDNA 56+ genes), 0493U (donor-derived cfDNA quantification) exemplify ctDNA/cfDNA uses
    Reported outputReported as presence/absence, percent donor-derived DNA, or quantitative disease burden depending on test
    cfDNA definition — donor-derived DNA percent for transplant monitoring and tumor detection
    DefinitioncfDNA: cell-free DNA from plasma used for tumor detection, quantification, or donor‑derived DNA percent for transplant monitoring (eg, 0493U)
    ApplicationsTransplant rejection surveillance and oncology MRD detection are primary clinical uses in the code list
    Output formatOften reported as percentage donor-derived DNA or binary/quantitative tumor burden
    Methylation analysis — profiling across thousands of sites reported with algorithmic scores
    DefinitionMethylation analysis: DNA methylation profiling across thousands of CpG sites reported with an algorithmic risk or detection score for conditions (eg, cancer, dementia, NASH, psychiatric disorders)
    Site-count examplesTests in the policy report site counts ranging from ~5,000 to >30,000 sites depending on indication (see codes 0506U, 0616U, 0617U, etc.)
    Reported outputAlgorithmic score reported as positive/negative risk or quantitative risk estimate
    Translocation analysis — detecting chromosomal translocations used in cancer diagnostics
    DefinitionTranslocation analysis: testing to detect chromosomal translocations (eg, NTRK, BCR/ABL1, PML/RARalpha) used in cancer diagnostics
    Code examplesCPT codes 81191–81194 (NTRK translocation analysis), 81315/81316 (PML/RARalpha) and other translocation-specific CPT entries are listed
    Clinical roleHelps identify targetable rearrangements and guide therapy selection or prognosis
    Common variants — testing limited to frequently observed pathogenic or clinically relevant variants
    DefinitionCommon variants testing: assays limited to frequently observed pathogenic or clinically relevant variants (examples include CYP2C9 *2/*3, G6PD A/A-)
    Use caseOften used for pharmacogenetic or carrier screens targeting known population variants
    DistinctionDifferent from full gene sequencing or copy number/structural analyses which assess the entire gene or genomic region
    Molecular pathology procedure levels — categorization by complexity/variant types
    ExamplesLevel 3: >10 SNPs or 2–10 methylated variants; Level 4: single exon or >10 amplicons; Level 6: analysis of 6–10 exons; Level 8/9: larger gene/exon counts and multiple-gene platforms
    ImplicationUse level descriptors when requesting authorization and to align test complexity with clinical indication
    Cytogenomic analysis / low-pass sequencing — genome-wide interrogation for CNV/LOH
    DefinitionCytogenomic analysis / low-pass sequencing: genome-wide interrogation for copy number variants and loss-of-heterozygosity using arrays or low-pass sequencing
    Use casesApplied for constitutional chromosomal abnormalities, tumor copy-number profiling, and detection of large-scale genomic changes
    Representative codes0221U (ABO NGS genotyping), 81228/81229 (cytogenomic microarray) and OGM entries represent genome-wide methods in the list
    Molecular pathology procedure levels (Level 6–9 examples)
    Level examples (6–9)Level 6 = analysis of 6–10 exons; Level 7 = 11–25 exons; Level 8 = 26–50 exons or multiple-gene platforms; Level 9 = >50 exons in a single gene
    ApplicationLevels used to classify molecular testing complexity and guide authorization documentation
    Codes81400–81406 and 81407–81408 correspond to molecular pathology procedure levels in the policy listings
    Exome/genome sequence analysis definition
    DefinitionExome/genome sequence analysis: comprehensive sequence analysis of coding regions (exome) or whole genome; may include comparator exomes/genomes for family members
    Codes81415/81416 for exome; 81425/81426 for genome; comparator exomes/genomes listed separately
    Re-evaluation81427 is the code for genome re-evaluation of a previously obtained genome sequence
    ACMG sequence variant interpretation reference
    Reference guidelineACMG/AMP 2015 Standards and guidelines for interpretation of sequence variants (Richards et al., 2015)
    UseReferenced as the standard for sequence variant interpretation in the policy references
    CitationRichards S, Aziz N, Bale S, et al. Genet Med. 2015;17(5):405-424.
    Genetic testing ethical guidance reference (AAP/ACMG)
    ReferenceAAP/ACMG technical report on ethical and policy issues in genetic testing and screening of children
    UseCited for guidance about testing minors and ethical considerations for predictive/prenatal testing of adult-onset conditions
    Citation exampleRoss LF, Saal HM, David KL, Anderson RR; American Academy of Pediatrics; American College of Medical Genetics and Genomics. Genet Med. 2013;15(3):234-245.

    Background and Rationale

    This policy provides general principles for evaluating genetic and other laboratory tests when specific coverage rules are not present: tests must have demonstrated clinical validity and clinical utility, be ordered for appropriate clinical indications (for example, diagnostic uncertainty, impact on management, prognosis, or reproductive decision‑making), and be performed in a CLIA‑approved laboratory. Pre‑test genetic counseling is recommended for prenatal and predictive testing and providers should document clinical features, family history, and the rationale supporting medical necessity when requesting prior authorization.

    Policy Dates and Revision History

    2026-05-01Effective DateLatest

    Policy M.89 became effective.

    2026-01-28Last Review

    Clinical and policy content was reviewed (last review date recorded).

    2027-01-01Next Review

    Scheduled next policy review date.

    References and policy notices are provided for providers to support authorization requests. The document cites professional society statements (NSGC, AAP/ACMG), the CDC ACCE framework, and other resources; it also includes the BCBSN medical policy disclaimer clarifying that medical policies are used to determine scientific validity and do not constitute medical advice or an authorization for benefits.